Seeking Alpha

Disclosure Insight's  Instablog

Disclosure Insight
Send Message
John P. Gavin, CFA, is the founder and CEO of Disclosure Insight®, an independent publisher of investment research. Mr. Gavin has spent his entire career of over 25 years in the financial services industry. Prior to starting “DI” in 2000, he worked as an equity analyst and portfolio manager... More
My company:
Disclosure Insight
My blog:
The D.I. Blog
  • FDA Advisory Committee Unanimously Recommends Approval of a Competitor to Onyx’s Only Approved Drug 0 comments
    Dec 7, 2011 4:24 PM | about stocks: PFE, ONXX

    As announced today by Pfizer (NYSE: PFE), the FDA’s Oncologic Drugs Advisory Committee voted unanimously that data for the investigational agent axitinib support a favorable benefit/risk profile for the treatment of patients with advanced renal cell carcinoma after failure of a first-line systemic therapy.

    Axitinib, if approved, would compete with Onyx Pharmaceuticals’ (NASDAQ: ONXX) Nexavar. Nexavar is ONXX’s only approved product (through a collaboration agreement with Bayer) that generated commercial revenue during 2010 and 9M11. Profit-sharing, cost reimbursement, and royalty revenue from the agreement accounted for all of 9M11 revenue.

    Here is PFE's press release on axitinib.

    Stocks: PFE, ONXX
Back To Disclosure Insight's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.